Synovus Financial Corp lifted its stake in shares of Boston Scientific Co. (NYSE:BSX) by 37.2% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 5,000 shares of the medical equipment provider’s stock after buying an additional 1,356 shares during the period. Synovus Financial Corp’s holdings in Boston Scientific were worth $191,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. FMR LLC increased its position in shares of Boston Scientific by 10.4% during the second quarter. FMR LLC now owns 156,622,452 shares of the medical equipment provider’s stock valued at $5,121,554,000 after buying an additional 14,711,069 shares during the period. BlackRock Inc. increased its position in shares of Boston Scientific by 2.9% during the second quarter. BlackRock Inc. now owns 109,355,395 shares of the medical equipment provider’s stock valued at $3,575,920,000 after buying an additional 3,062,924 shares during the period. Janus Henderson Group PLC increased its position in shares of Boston Scientific by 0.7% during the second quarter. Janus Henderson Group PLC now owns 41,739,459 shares of the medical equipment provider’s stock valued at $1,364,885,000 after buying an additional 273,848 shares during the period. Standard Life Aberdeen plc increased its position in shares of Boston Scientific by 1.3% during the second quarter. Standard Life Aberdeen plc now owns 13,998,353 shares of the medical equipment provider’s stock valued at $457,817,000 after buying an additional 178,939 shares during the period. Finally, Putnam Investments LLC increased its position in shares of Boston Scientific by 14.4% during the second quarter. Putnam Investments LLC now owns 10,003,513 shares of the medical equipment provider’s stock valued at $327,115,000 after buying an additional 1,258,287 shares during the period. Institutional investors own 91.24% of the company’s stock.

BSX has been the topic of several research analyst reports. Zacks Investment Research cut shares of Boston Scientific from a “buy” rating to a “sell” rating in a research report on Tuesday, July 17th. SunTrust Banks upped their price objective on shares of Boston Scientific to $39.00 and gave the stock a “buy” rating in a report on Monday, July 23rd. Royal Bank of Canada upped their price objective on shares of Boston Scientific to $36.00 and gave the stock a “top pick” rating in a report on Monday, July 23rd. Piper Jaffray Companies upped their price objective on shares of Boston Scientific to $38.00 and gave the stock an “overweight” rating in a report on Thursday, July 26th. Finally, Morgan Stanley upped their price objective on shares of Boston Scientific from $33.00 to $38.00 and gave the stock an “overweight” rating in a report on Thursday, July 26th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have issued a buy rating and three have issued a strong buy rating to the company. Boston Scientific has an average rating of “Buy” and a consensus price target of $39.00.

In other news, EVP David A. Pierce sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $36.02, for a total value of $180,100.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP John Bradley Sorenson sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $35.86, for a total transaction of $358,600.00. Following the completion of the transaction, the senior vice president now owns 44,636 shares in the company, valued at approximately $1,600,646.96. The disclosure for this sale can be found here. In the last quarter, insiders sold 414,000 shares of company stock worth $15,347,937. Insiders own 0.73% of the company’s stock.

Shares of NYSE BSX opened at $38.60 on Friday. The company has a market capitalization of $52.52 billion, a PE ratio of 26.54, a PEG ratio of 2.49 and a beta of 0.68. Boston Scientific Co. has a 52-week low of $24.54 and a 52-week high of $39.44. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.56 and a current ratio of 0.78.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 24th. The medical equipment provider reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.01. The firm had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.40 billion. Boston Scientific had a net margin of 6.93% and a return on equity of 26.44%. The business’s revenue was up 7.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.31 earnings per share. On average, research analysts anticipate that Boston Scientific Co. will post 1.39 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Boston Scientific Co. (BSX) Shares Bought by Synovus Financial Corp” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.dailypolitical.com/2018/11/10/boston-scientific-co-bsx-shares-bought-by-synovus-financial-corp.html.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Further Reading: How is an ETF different from a mutual fund?

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.